From: Wnt/beta-catenin pathway: modulating anticancer immune response
Mechanism of action | Agent Company name | Stage of clinical development | Status | Identifier | Details |
---|---|---|---|---|---|
PORCN inhibitor (blocks the secretion of Wnt ligands) PORCN inhibitor | WNT974 Array Biopharma | Phase 1 | Active, not recruiting | NCT02278133 | In combination with LGX818 and cetuximab; patients with BRAF-mut mCRC and WNT pathway mutations |
Phase 2 | Withdrawn | NCT02649530 | Patients with metastatic HNSCC; single-arm, non-randomized | ||
LGK974 Novartis | Phase 1 | Recruiting | NCT01351103 | Documented BRAF mut for mCRC and pancreatic cancer; tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling; trial was suspended due to unknown reasons | |
ETC-1922159 | Phase 1a/1b | Recruiting | NCT02521844 | Locally advanced or metastatic solid tumors | |
WNT-5a mimetic | Foxy-5 Wnt Research AB | Phase 1 | Completed | NCT02020291 | Metastatic breast, mCRC, or prostate cancer with loss of or reduced Wnt5a protein expression in IHC analysis |
Phase 1 | Recruiting | NCT02655952 | Metastatic breast, mCRC, or prostate cancer with loss of or reduced Wnt5a protein expression in IHC analysis | ||
Sam68 modulator: interferes with the alternative splicing of Tcf | CWP232291 JW Pharmaceutical | Phase 1 | Completed | NCT01398462 | Relapsed or refractory AML, CMML, MDS, or high-risk myelofibrosis |
Phase1a/1b | Recruiting | NCT02426723 | Relapsed or refractory MM | ||
Wnt inhibitor | CGX1321 Curegenix Inc. | Phase 1 | Recruiting | NCT02675946 | Locally advanced or metastatic solid tumors |
Inhibition of β-catenin recruitment through antagonizing its coactivator CBP (the binding protein of cAMP response element-binding protein CREB) | PRI-724 Prism Pharma Co. | Phase 1b | Completed | NCT01764477 | Advanced or metastatic pancreatic adenocarcinoma, in combination with gemcitabine in the second line of treatment |
Phase 1/2 | Active, not recruiting | NCT01606579 | Advanced myeloid malignancies | ||
Randomized phase 2 | Withdrawn | NCT02413853 | Advanced mCRC, in combination with mFOLFOX6 + bevacizumab, in the first line of treatment | ||
Phase 1a/1b | Terminated | NCT01302405 | Phase 1a: any advanced neoplasm Phase 1b: only patients with mCRC | ||
Humanized monoclonal antibody OTSA101 against FZD10 and labeled with Y90 | OTSA101 OncoTherapy Science | Phase 1 | Active, not recruiting | NCT01469975 | In patients with doxorubicin and ifosfamide-refractory synovial sarcoma |
Monoclonal antibody against frizzled receptors | OMP-18R5 (Vantictumab) OncoMed Pharmaceuticals | Phase1 | Recruiting | NCT01973309 | In patients with metastatic breast cancer in combination with paclitaxel |
Humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 | DKN-01 Leap Therapeutics, Inc. | Phase 1 | Recruiting | NCT02013154 | In combination with paclitaxel in esophageal neoplasms, adenocarcinoma of the gastroesophageal junction, gastroesophageal cancer, squamous cell carcinoma, and gastric adenocarcinoma |
Phase 1 | Recruiting | NCT02375880 | In combination with gemcitabine and Cisplatin in carcinoma of intrahepatic and extra-hepatic biliary systems, carcinoma of gallbladder, bile duct cancer, and cholangiocarcinoma | ||
Antagonizes Wnt signaling through competes with the membrane-bound Fzd8 (decoy receptor) | OMP-54F28 (ipafricept) OncoMed Pharmaceuticals | Phase 1b | Active, not recruiting | NCT02069145 | In patients with locally advanced or metastatic hepatocellular cancer, in combination with sorafenib |
Phase 1b | Recruiting | NCT02092363 | In patients with recurrent platinum-sensitive ovarian cancer, in combination with paclitaxel and carboplatin | ||
Phase 1b | Active, not recruiting | NCT02050178 | In patients with untreated stage IV metastatic pancreatic cancer, in combination with gemcitabine and nab-paclitaxel | ||
Phase 1 | Completed | NCT01608867 | Metastatic and unresectable refractory solid tumors |